VCEL Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Vericel Corporation (VCEL) is currently trading at $48.05 as of 2025-03-24. The stock has shown recent selling pressure, with the Relative Strength Index (RSI) at 36.65, indicating potential oversold conditions but not yet reaching extreme levels. The stock recently crossed below its 200-day moving average, a bearish signal.
Fibonacci Levels:
The Fibonacci levels suggest key support and resistance points. The pivot level is at $47.10, with resistance at $48.73 and $49.73, and support at $45.48 and $44.48.
News Sentiment:
Vericel is scheduled to present at multiple investor conferences, which could positively impact the stock if the presentations are well-received. However, the recent price action and technical indicators suggest caution.
Conclusion:
Based on the analysis, VCEL is expected to test the lower Fibonacci support levels next week. The stock is likely to decline to $44.48.
Recommendation: Sell VCEL if it fails to hold above the pivot level of $47.10.
VCEL Similar Chart Price Prediction
The price of VCEL is predicted to go up -29.73%, based on the high correlation periods with APTO. The similarity of these two price pattern on the periods is 98.53%.
VCEL
APTO
Down: -29.73%Similarity: 98.53%
VCEL Revenue Forecast
VCEL EPS Forecast
VCEL FAQs
What is VCEL revenue forecast for next quarter？
What is VCEL eps forecast for next quarter？
VCEL Analyst's Forecast
Samuel Brodovsky
Truist Securities
Strong Buy
2024-12-18
Price Target
$61 → $67
Upside
+19.11%
Truist analyst Richard Newitter raised the firm's price target on Vericel to $67 from $61 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as "one of the better/safer houses" in healthcare given its lower "front-line" exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an "innovation segment" with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be "poised to heat up".
Ryan Zimmerman
BTIG
Strong Buy
2024-11-26
Price Target
$56 → $66
Upside
+12.34%
